ProKidney Corp.
$2.1
▲
8.57%
2026-04-21 08:57:00
prokidney.com
NCM: PROK
Explore ProKidney Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$634.02 M
Current Price
$2.1
52W High / Low
$7.13 / $0.54
Stock P/E
—
Book Value
$-7.13
Dividend Yield
—
ROCE
-54.13%
ROE
-43.17%
Face Value
—
EPS
$-0.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
231
Beta
1.86
Debt / Equity
1.34
Current Ratio
9.13
Quick Ratio
9.13
Forward P/E
-2.67
Price / Sales
657.79
Enterprise Value
$1.32 B
EV / EBITDA
-8.35
EV / Revenue
1,481.3
Rating
None
Target Price
$6.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
| 2. | Context Therapeutics Inc. | $2.26 | — | $223.27 M | — | -65.65% | -46.39% | $3.62 / $0.49 | $0.66 |
| 3. | Tango Therapeutics, Inc. | $26.39 | — | $3.8 B | — | -29.52% | -37.23% | $26.81 / $1.03 | $2.55 |
| 4. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
| 5. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
| 6. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 7. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.23 M | 0.22 M | 0.22 M | 0.23 M | 0.08 M | — |
| Operating Profit | -45.37 M | -38.54 M | -39.71 M | -41.39 M | -51.57 M | — |
| Net Profit | -19.23 M | -16.47 M | -16.55 M | -16.73 M | -21.28 M | — |
| EPS in Rs | -0.14 | -0.12 | -0.12 | -0.12 | -0.15 | -0.14 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.89 M | 0.08 M | 0 M | 0 M |
| Operating Profit | -165.01 M | -183.68 M | -151.52 M | -153.01 M |
| Net Profit | -68.99 M | -61.19 M | -35.47 M | -108.03 M |
| EPS in Rs | -0.49 | -0.43 | -0.25 | -0.76 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 335.57 M | 441.07 M | 420.55 M | 518 M |
| Total Liabilities | 34.78 M | 39.44 M | 29.22 M | 13.06 M |
| Equity | -1.01 B | -994.95 M | -1.1 B | -1.1 B |
| Current Assets | 280.68 M | 395.88 M | 374.15 M | 504.72 M |
| Current Liabilities | 30.74 M | 36.22 M | 25.04 M | 10.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -120.12 M | -126.35 M | -90.07 M | -77.09 M |
| Investing CF | 103.97 M | 20.41 M | -329.98 M | -1.74 M |
| Financing CF | 25.57 M | 144.41 M | -9.55 M | 548.52 M |
| Free CF | -135.31 M | -155.86 M | -124.27 M | -78.94 M |
| Capex | -15.2 M | -29.51 M | -34.2 M | -1.85 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 1075% | — | — | — |
| Earnings Growth % | -12.75% | -72.51% | 67.17% | — |
| Profit Margin % | -7725.2% | -80507.89% | — | — |
| Operating Margin % | -18477.83% | -241678.95% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -16194.74% | -208542.11% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.